# Fasenra: An Asthma Study

> **NCT07654842** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Endeavor Health** · enrollment: 40 (estimated)

## Conditions studied

- Eosinophilic Asthma
- Severe Asthma
- Severe Eosinophilic Asthma
- Asthma

## Interventions

- **DRUG:** Budesonide-albuterol
- **DRUG:** Benralizumab

## Key facts

- **NCT ID:** NCT07654842
- **Lead sponsor:** Endeavor Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-07-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07654842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07654842, "Fasenra: An Asthma Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07654842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*